HTFL
BEARISH
$26.95
Live
Heartflow, Inc. · NASDAQ
Target $37.67
(+39.8%)
$20.13
52W Range
$41.22
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 11, 2026
Market cap
$2.31B
P/E
N/A
ROE
-111.4%
Profit margin
-66.3%
Debt/Equity
0.07
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
HTFL exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational inefficiency. While the company maintains a strong liquidity position (Current Ratio 5.20) and impressive revenue growth of 40.5%, these are offset by deep negative profit margins (-66.35%) and a high Price/Sales multiple of 13.13. The combination of heavy insider selling ($62.54M) and consistent earnings misses suggests a significant disconnect between analyst optimism and internal sentiment.
Key Strengths
Strong YoY revenue growth of 40.50%
High gross margins (76.80%) indicating a scalable product
Very low debt-to-equity ratio (0.07)
Excellent short-term liquidity (Current Ratio 5.20)
Positive recent short-term price momentum (1M Change +21.3%)
Key Risks
Critical financial health (Piotroski F-Score 1/9)
Severe profitability issues with -66.35% profit margins
Aggressive valuation (P/S 13.13) relative to earnings performance
Heavy insider liquidation ($62.54M in sells, 0 buys)
Poor earnings track record with an average surprise of -178.71%
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
28
Weak
20
75
30
15
0
AI Verdict
Speculative / High Risk
Key drivers: Revenue growth, Piotroski F-Score, Insider selling, Negative margins
Confidence
90%
Value
20/100
Graham Number N/A due to negative earnings; trades at a steep premium to book value.
Positives
No standout positives identified.
Watchpoints
- P/S ratio of 13.13 is excessive
- P/B ratio of 7.65 is high
- No P/E due to lack of profitability
Future
75/100
Growth is the primary bull case, but monetization is lagging.
Positives
- 40.5% YoY revenue growth
- Strong Q/Q growth trajectory
Watchpoints
- Forward P/E remains deeply negative (-89.77)
Past
30/100
Historical performance shows a trend of missing estimates and price depreciation.
Positives
- Recent 1-month recovery
Watchpoints
- 1Y return of -10.1%
- Consistent earnings misses (1/4 beats)
Health
15/100
Despite high liquidity, the F-Score indicates a company in financial distress or severe operational decline.
Positives
- Low debt
- High current ratio
Watchpoints
- Piotroski F-Score 1/9
- ROE of -111.37%
Dividend
0/100
Non-dividend paying growth stock.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$26.95
Analyst Target
$37.67
Upside/Downside
+39.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for HTFL and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
HTFL
Heartflow, Inc.
Primary
|
-10.1% | -10.1% | -10.1% | -19.5% | +21.3% | +8.5% |
|
ATEC
Alphatec Holdings, Inc.
Peer
|
+4.7% | +20.4% | +33.9% | +44.4% | -24.8% | -11.9% |
|
DAWN
Day One Biopharmaceuticals, Inc.
Peer
|
-8.7% | +69.0% | +205.7% | +189.6% | +0.6% | +0.1% |
|
APLS
Apellis Pharmaceuticals, Inc.
Peer
|
-59.8% | -70.9% | -22.3% | -23.8% | -15.1% | -5.6% |
|
BHC
Bausch Health Companies Inc.
Peer
|
-78.1% | -29.4% | -24.3% | -12.7% | -17.7% | -15.3% |
HTF
Heartflow, Inc.
Primary
5Y
-10.1%
3Y
-10.1%
1Y
-10.1%
6M
-19.5%
1M
+21.3%
1W
+8.5%
ATE
Alphatec Holdings, Inc.
Peer
5Y
+4.7%
3Y
+20.4%
1Y
+33.9%
6M
+44.4%
1M
-24.8%
1W
-11.9%
DAW
Day One Biopharmaceuticals, Inc.
Peer
5Y
-8.7%
3Y
+69.0%
1Y
+205.7%
6M
+189.6%
1M
+0.6%
1W
+0.1%
APL
Apellis Pharmaceuticals, Inc.
Peer
5Y
-59.8%
3Y
-70.9%
1Y
-22.3%
6M
-23.8%
1M
-15.1%
1W
-5.6%
BHC
Bausch Health Companies Inc.
Peer
5Y
-78.1%
3Y
-29.4%
1Y
-24.3%
6M
-12.7%
1M
-17.7%
1W
-15.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-89.77
PEG Ratio
N/A
P/B Ratio
7.65
P/S Ratio
13.13
EV/Revenue
12.25
EV/EBITDA
-34.43
Market Cap
$2.31B
Profitability
Profit margins and return metrics
Profit Margin
-66.35%
Operating Margin
-36.13%
Gross Margin
76.8%
ROE
-111.37%
ROA
-16.75%
Growth
Revenue and earnings growth rates
Revenue Growth
+40.5%
Earnings Growth
N/A
Q/Q Revenue Growth
+40.46%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.07
Low debt
Current Ratio
5.2
Strong
Quick Ratio
4.87
Excellent
Cash/Share
$2.06
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
79.5%
Op. Margin
-36.1%
Net Margin
-49.7%
Total Assets
$0.4B
Liabilities
$0.1B
Equity
$0.3B
Debt/Equity
0.20x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
118%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-14
$N/A
2026-03-18
$-0.12
+23.2% surprise
2025-11-12
$-1.04
-141.9% surprise
2025-09-19
$-1.1
-417.4% surprise
Healthcare Sector Comparison
Comparing HTFL against 226 companies in the Healthcare sector
(19 bullish, 76 neutral, 131 bearish)
Return on Equity (ROE)
-111.37%
This Stock
vs
-40.43%
Sector Avg
+175.5%
(Excellent)
Profit Margin
-66.35%
This Stock
vs
-18.65%
Sector Avg
+255.8%
(Superior)
Debt to Equity
0.07
This Stock
vs
4.61
Sector Avg
-98.4%
(Less Debt)
Revenue Growth
40.5%
This Stock
vs
97.21%
Sector Avg
-58.3%
(Slower)
Current Ratio
5.2
This Stock
vs
3.51
Sector Avg
+48.1%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
HTFL
Heartflow, Inc.
|
BEARISH | $2.31B | - | -111.4% | -66.3% | $26.95 | |
|
ATEC
Alphatec Holdings, Inc.
|
BEARISH | $2.32B | - | -540.4% | -21.3% | $15.62 | Compare |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
NEUTRAL | $2.22B | - | -22.7% | -67.8% | $21.46 | Compare |
|
APLS
Apellis Pharmaceuticals, Inc.
|
BEARISH | $2.42B | 105.22 | 7.5% | 2.2% | $18.94 | Compare |
|
BHC
Bausch Health Companies Inc.
|
BEARISH | $2.19B | 6.79 | 563.2% | 3.6% | $5.91 | Compare |
HTFL
Heartflow, Inc.
BEARISH
Mkt Cap
$2.3B
P/E
-
ROE
-111.4%
Price
$26.95
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | ROGERS CAMPBELL D M.D. | Officer | Sale | 64,533 | $1,590,093 |
| 2026-04-01 | ROGERS CAMPBELL D M.D. | Officer | Option Exercise | 67,017 | $150,556 |
| 2026-03-19 | ROGERS CAMPBELL D M.D. | Officer | Sale | 64,533 | $1,658,033 |
| 2026-03-19 | ROGERS CAMPBELL D M.D. | Officer | Option Exercise | 67,017 | $148,778 |
| 2026-03-18 | FARQUHAR JOHN C. M. | Chief Executive Officer | Sale | 9,725 | $243,125 |
| 2026-03-11 | BARABE TIMOTHY CRAIG | Director | Option Exercise | 8,667 | $19,241 |
| 2026-03-10 | FARQUHAR JOHN C. M. | Chief Executive Officer | Sale | 12,837 | $290,886 |
| 2026-03-06 | FARQUHAR JOHN C. M. | Chief Executive Officer | Stock Award | 2,631 | $60,460 |
| 2026-03-05 | CULLIVAN JULIE ANNE | Director | Sale | 9,122 | $228,050 |
| 2026-02-17 | BARABE TIMOTHY CRAIG | Director | Option Exercise | 2,497 | $20,800 |
| 2026-02-12 | ROGERS CAMPBELL D M.D. | Officer | Sale | 65,153 | $1,595,486 |
| 2026-02-12 | ROGERS CAMPBELL D M.D. | Officer | Option Exercise | 67,016 | $391,398 |
| 2026-02-10 | FARQUHAR JOHN C. M. | Chief Executive Officer | Sale | 22,562 | $619,553 |
| 2026-02-06 | ROGERS CAMPBELL D M.D. | Officer | Stock Award | 54,073 | - |
| 2026-02-06 | JONES MARIE L | Officer | Stock Award | 21,629 | - |
ROGERS CAMPBELL D M.D.
Officer
2026-04-01
64,533 shares
·
$1,590,093
ROGERS CAMPBELL D M.D.
Officer
2026-04-01
67,017 shares
·
$150,556
ROGERS CAMPBELL D M.D.
Officer
2026-03-19
64,533 shares
·
$1,658,033
ROGERS CAMPBELL D M.D.
Officer
2026-03-19
67,017 shares
·
$148,778
FARQUHAR JOHN C. M.
Chief Executive Officer
2026-03-18
9,725 shares
·
$243,125
BARABE TIMOTHY CRAIG
Director
2026-03-11
8,667 shares
·
$19,241
FARQUHAR JOHN C. M.
Chief Executive Officer
2026-03-10
12,837 shares
·
$290,886
FARQUHAR JOHN C. M.
Chief Executive Officer
2026-03-06
2,631 shares
·
$60,460
CULLIVAN JULIE ANNE
Director
2026-03-05
9,122 shares
·
$228,050
BARABE TIMOTHY CRAIG
Director
2026-02-17
2,497 shares
·
$20,800
ROGERS CAMPBELL D M.D.
Officer
2026-02-12
65,153 shares
·
$1,595,486
ROGERS CAMPBELL D M.D.
Officer
2026-02-12
67,016 shares
·
$391,398
FARQUHAR JOHN C. M.
Chief Executive Officer
2026-02-10
22,562 shares
·
$619,553
ROGERS CAMPBELL D M.D.
Officer
2026-02-06
54,073 shares
JONES MARIE L
Officer
2026-02-06
21,629 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
6 analysts
JP Morgan
2026-03-19
Overweight
Overweight
Canaccord Genuity
2026-03-19
Buy
Buy
Wells Fargo
2026-03-19
Overweight
Overweight
Canaccord Genuity
2026-03-09
Buy
Buy
Wells Fargo
2026-01-28
Overweight
Canaccord Genuity
2025-11-13
Buy
Buy
JP Morgan
2025-11-13
Overweight
Overweight
Stifel
2025-11-13
Buy
Buy
Past News Coverage
Recent headlines mentioning HTFL from our newsroom.
Newest → oldest
No matching news yet.